EV Biologics Signs MSA with LONZA Cell & Gene Therapy
Press Release | 05/17/2022
HOUSTON, TX / ACCESSWIRE / May 17, 2022 / EV Biologics Corp, OTC PINK:YECO, today announced that it has signed a Manufacturing Services Agreement (MSA) with Lonza for development of stem/progenitor cell-derived nanotherapeutics and scalable biomanufacturing process.
The MSA enables EV Biologics to accelerate its nanotherapeutic biomanufacturing process and producer-cell line development through Lonza's global infrastructure and deep expertise in cell and gene therapy.
EV Biologics has been developing nanotherapeutic-producer cells and optimizing a process for isolation of primary cells from tissue and expansion of cell banks using defined cell culture conditions. The Company is very pleased to announce that advancing its relationship with Lonza will accelerate development and implementation of rigorous upstream and downstream biomanufacturing processes that will facilitate production of more consistent nanotherapeutic candidates.
CEO, Daniel Mckinney, said "We are very excited to enter the next phase of our business relationship with Lonza, the world's premier biomanufacturing firm for further process development. This represents a significant step toward our goal of developing high-quality nanotherapeutics for a broad range of clinical conditions. Furthermore, we are maximizing our resources and multiplying our efficiency by leveraging the assets of best-in-class partners like Lonza, rather than investing tens of millions in our own physical infrastructure for laboratory and manufacturing facilities."
About the Company
EV Biologics (formerly Yulong Eco-Materials Limited) is a Wyoming, USA domiciled Biotechnology Company, developing a range of nanotherapeutics to substantially enhance the intrinsic bioactivity of stem and progenitor cell-derived nanoparticles. The Company is also developing biomanufacturing, bioinformatic and bioengineering innovations to optimize production of nanoparticle therapeutics and biologics. These versatile therapeutic platforms will enable generation of nanotherapeutics targeting a broad range of regenerative medicine and longevity applications.
About Lonza
Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. They focus on enabling treatments that prevent illness and support healthier lifestyles. They optimize scientific innovation and manufacturing technology to enable our customers to serve their patients and consumers.
They provide a wide range of services and products from early phase discovery to custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. Their scale and resources mean they can provide a one-stop solution for our customers to help people get well, feel well, and stay well. In 2021, we supported more than 780 preclinical and clinical small and large molecules, more than 245 commercial small and large molecules and produced around 250 billion capsules.
Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately 16,000 employees (full-time equivalent), they comprise high-performing teams
and individual talent that make a meaningful difference to their own businesses, as well as to the communities in which they operate. Their business benefits from global supply chains, but have worked to maintain the agility to address marketplace needs on a local level.
A firm commitment to responsible business and sustainability underpins everything they do. Minimizing their impact on the environment, conserving energy and natural resources, and helping to improve life quality are all central to our culture. Lonza's Vision Zero initiative is a prime example, as they strive to achieve zero workplace accidents and injuries, zero environmental incidents, zero product transportation incidents and zero manufacturing process incidents. They work to attract and retain the best talent, to make a meaningful difference to their own business, as well as to the communities in which they operate.
Lonza generated sales of CHF 5.4 billion with a CORE EBITDA of CHF 1.7 billion in Full-Year 2021. The Lonza shares are listed on the SIX Swiss Exchange and Swiss Market Index (SMI). They also maintain a secondary listing on the SGX Singapore Exchange. For more information about Lonza: www.lonza.com
AI
